Akt1
Akt1
Overview
Akt1, also known as protein kinase B alpha, is a serine/threonine kinase that functions as a central node in the PI3K/AKT signaling network. It integrates upstream cues from growth factors, cytokines, metabolic signals, and stress responses to regulate cell survival, proliferation, metabolism, migration, autophagy, and apoptosis. In biomedical research, Akt1 is frequently studied alongside PTEN, mTOR, ERK, EGFR, SRC, GSK3β, and cGAS-STING-related signaling because changes in its phosphorylation state often reflect pathway activation or suppression.
As a target, Akt1 is especially prominent in cancer, metabolic disease, neuroinflammation, fibrosis, and tissue repair studies. Recent work has used Akt1 as a mechanistic readout for drug response, pathway crosstalk, and resistance biology, including contexts involving PD-L1 expression, FLT3 signaling, VEGF-associated neurobiology, and PI3K/AKT/mTOR-driven phenotypes. The studies summarized below largely focus on Akt1 phosphorylation or pathway modulation rather than direct structural characterization of the protein.
Recent Publications Focus
Below is a summary of the newest research publications targeting Akt1 (sorted by publication date).
Recent research demonstrates AKT1's centrality as a therapeutic node across oncology, neurology, and metabolic disease. In cancer applications, AKT1 serves as both a direct target and a critical mediator of treatment resistance. A novel RIPK1-mediated targeting chimera (RIMTAC) platform induced potent degradation of AKT alongside BRD4 and JAK1 [42417401], while exosomal transfer of phosphorylated AKT emerged as a key driver of doxorubicin resistance in breast cancer, with AKT inhibition reversing this resistance [42417926]. In hepatocellular carcinoma, the CNOT9 oncogene promotes progression through suppression of the PTEN/AKT/p53 axis [42384246], and PRXL2B facilitates resistance to oncolytic adenovirus therapy via PI3K/AKT/PD-L1 signaling [42161529]. A dual BRD4/AKT inhibitor (compound 21d) demonstrated superior efficacy against metastatic castration-resistant prostate cancer by overcoming c-MYC-driven resistance mechanisms [41966583]. CAMK2D isoform 15 was identified as a mediator of gefitinib resistance in lung adenocarcinoma through AKT phosphorylation [42152470], while lenvatinib combined with PD-1 blockade suppressed immunosuppressive macrophages in gastric cancer by inhibiting PDGFR/FGFR-dependent AKT signaling [42044259]. Translation inhibitors combined with venetoclax and cytarabine showed promise in acute myeloid leukemia through regulation of AKT activity [42118656].
In neuroprotection, AKT1 emerged as a convergence point for multiple therapeutic pathways. Ergothioneine conferred neuroprotection in ischemic stroke through activation of the PI3K/Akt/Nrf2 pathway [42214028], while butyrate reduced amyloid-beta accumulation at the blood-brain barrier by activating AKT and ERK phosphorylation, with implications for Alzheimer's disease [42166642]. NADPH similarly protected against cerebral ischemia via AKT1-mediated mechanisms that preserved barrier integrity and stimulated angiogenesis [41638470]. Platelet-rich plasma-primed bone marrow mesenchymal stem cell-derived exosomes promoted spinal cord injury recovery through the miR-29a-3p/PTEN/PI3K/Akt/mTOR axis [42165939], and electroacupuncture ameliorated depression-related behaviors by enhancing autophagy via the VEGF/AKT1/ERK pathway [42149321].
Metabolic and inflammatory disease contexts similarly engaged AKT1 across diverse intervention strategies. luteolin-loaded protein composite gels enhanced adipocyte insulin sensitivity through increased p-Akt expression [42283235], and Pueraria lobata polysaccharides mitigated obesity through hepatic FGF21 signaling pathway activation involving AKT [41819911]. Isoprenaline alleviated diabetic kidney disease by regulating the cGAS-STING pathway through multi-target coordination including AKT1 [41795784], while CHI3L1 enhanced profibrotic signaling through the AKT pathway in pulmonary fibrosis [42048160]. Paeonol suppressed endometrial stromal cell activation via AKT1 in intrauterine adhesion models [42062178].
Network pharmacology approaches further established AKT1 as a central hub in therapeutic development. A polyherbal nutraceutical formula (Vernolac) was computationally identified to exert anticancer effects through multiple pathways with AKT1 as a key node [42384725], while ginger processing of Magnolia officinalis bark modulated AKT1 among core targets to enhance gastrointestinal function [41520497]. Notably, masitinib induced AKT phosphorylation through a VPS34 and rapamycin-sensitive pathway independent of class I PI3K, operating via lysosomal accumulation mechanisms [42009094]. Collectively, these studies establish AKT1 as a versatile therapeutic node amenable to direct inhibition, indirect pathway modulation, and targeting through emerging degradation platforms across diverse disease contexts.